相似文献
1
Parkinson's disease in the acute hospital.
Clin Med (Lond). 2011 Feb;11(1):84-8. doi: 10.7861/clinmedicine.11-1-84.
2
Medication costs following subthalamic nucleus deep brain stimulation for Parkinson's disease.
Mov Disord. 2014 Feb;29(2):275-6. doi: 10.1002/mds.25504. Epub 2013 May 21.
3
Deep-brain stimulation for Parkinson's disease.
N Engl J Med. 2012 Oct 18;367(16):1529-38. doi: 10.1056/NEJMct1208070.
4
Deep brain stimulation for advanced Parkinson's disease.
Lancet Neurol. 2010 Jun;9(6):558-9. doi: 10.1016/S1474-4422(10)70108-3. Epub 2010 Apr 29.
5
Parkinson's Disease.
N Engl J Med. 2024 Aug 1;391(5):442-452. doi: 10.1056/NEJMra2401857.
6
New research holds promise for Parkinson's treatment. New drugs and stem cell research offer encouraging glimpses of future therapies.
Duke Med Health News. 2013 Dec;19(12):1-2.
7
Parkinson disease: deep brain stimulation versus best medical therapy for PD.
Nat Rev Neurol. 2010 Oct;6(10):530-2. doi: 10.1038/nrneurol.2010.128.
8
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Mov Disord. 2011 Mar;26(4):664-70. doi: 10.1002/mds.23524. Epub 2011 Apr 5.
9
Variable frequency stimulation of subthalamic nucleus for freezing of gait in Parkinson's disease.
Parkinsonism Relat Disord. 2015 Dec;21(12):1471-2. doi: 10.1016/j.parkreldis.2015.10.002. Epub 2015 Oct 20.
10
Functional peak dose dyskinesia in patients with Parkinson's disease.
Parkinsonism Relat Disord. 2009 Jul;15(6):475-6. doi: 10.1016/j.parkreldis.2008.09.006. Epub 2008 Dec 11.
本文引用的文献
1
Treatment of dysautonomia associated with Parkinson's disease.
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S224-32. doi: 10.1016/S1353-8020(09)70820-X.
2
The pragmatic use of apomorphine at the end of life.
Palliat Med. 2009 Dec;23(8):777-9. doi: 10.1177/0269216309106979. Epub 2009 Oct 16.
3
The number and nature of emergency department encounters in patients with deep brain stimulators.
J Neurol. 2010 Jan;257(1):122-31. doi: 10.1007/s00415-009-5343-8.
4
The place of death in Parkinson's disease.
Age Ageing. 2009 Sep;38(5):617-9. doi: 10.1093/ageing/afp123. Epub 2009 Jul 23.
5
Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
Mov Disord. 2009 May 15;24(7):993-1000. doi: 10.1002/mds.22450.
6
Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis.
J Clin Neurosci. 2009 Feb;16(2):335-7. doi: 10.1016/j.jocn.2008.02.015. Epub 2008 Dec 3.
7
The parkinsonism-hyperpyrexia syndrome.
Neurocrit Care. 2009;10(1):136-40. doi: 10.1007/s12028-008-9125-4. Epub 2008 Aug 20.
8
Impaired attention predicts falling in Parkinson's disease.
Parkinsonism Relat Disord. 2009 Feb;15(2):110-5. doi: 10.1016/j.parkreldis.2008.03.010. Epub 2008 May 19.
9
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005.
10
The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia.
Palliat Med. 2007 Mar;21(2):163-4.
Zotero 插件